SWM
UTHR icon

SHP Wealth Management’s United Therapeutics UTHR Stock Holding History

SHP Wealth Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63K Buy
3
+2
+200% +$1.13K ﹤0.01% 1457
2026
Q1 		$593 Sell
1
-1
-50% -$498 ﹤0.01% 1589
2025
Q4 		$974 Buy
+2
New +$931 ﹤0.01% 1263

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

SHP Wealth Management's UTHR Position: Q2 2026 in Review

SHP Wealth Management increased its United Therapeutics (UTHR) stake by 200% in Q2 2026, buying an estimated $1.13K and bringing the position to 3 shares worth $1.63K. The position accounts for ﹤0.01% of the portfolio, ranked #1457.

SHP Wealth Management first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • SHP Wealth Management held 3 shares of United Therapeutics worth $1.63K as of Q2 2026.
  • SHP Wealth Management bought 2 United Therapeutics shares in Q2 2026, an estimated $1.13K.
  • United Therapeutics made up ﹤0.01% of SHP Wealth Management's portfolio in Q2 2026, its #1457 holding.
  • SHP Wealth Management first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on SHP Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.